NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their price objective on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

NBY opened at $0.71 on Friday. The stock has a market capitalization of $3.50 million, a price-to-earnings ratio of -0.01 and a beta of 0.73. The company has a fifty day moving average of $0.64 and a 200 day moving average of $1.60. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $12.07.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.